Teva Pharmaceutical Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $38.67 billion. The enterprise value is $51.85 billion.

Market Cap	38.67B
Enterprise Value	51.85B

Important Dates

The next confirmed earnings date is Wednesday, July 29, 2026, before market open.

Earnings Date	Jul 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Teva Pharmaceutical has 1.16 billion shares outstanding. The number of shares has increased by 2.93% in one year.

Current Share Class	n/a
Shares Outstanding	1.16B
Shares Change (YoY)	+2.93%
Shares Change (QoQ)	+0.51%
Owned by Insiders (%)	0.43%
Owned by Institutions (%)	69.69%
Float	1.08B

Valuation Ratios

The trailing PE ratio is 24.80 and the forward PE ratio is 15.42. Teva Pharmaceutical's PEG ratio is 3.78.

PE Ratio	24.80
Forward PE	15.42
PS Ratio	2.23
Forward PS	2.32
PB Ratio	4.70
P/TBV Ratio	n/a
P/FCF Ratio	33.00
P/OCF Ratio	22.56
PEG Ratio	3.78

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.36, with an EV/FCF ratio of 44.24.

EV / Earnings	33.13
EV / Sales	2.99
EV / EBITDA	10.36
EV / EBIT	12.94
EV / FCF	44.24

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 2.06.

Current Ratio	1.01
Quick Ratio	0.53
Debt / Equity	2.06
Debt / EBITDA	3.29
Debt / FCF	14.44
Interest Coverage	4.48

Financial Efficiency

Return on equity (ROE) is 21.60% and return on invested capital (ROIC) is 18.63%.

Return on Equity (ROE)	21.60%
Return on Assets (ROA)	6.38%
Return on Invested Capital (ROIC)	18.63%
Return on Capital Employed (ROCE)	15.11%
Weighted Average Cost of Capital (WACC)	7.48%
Revenue Per Employee	$511,016
Profits Per Employee	$46,097
Employee Count	33,950
Asset Turnover	0.44
Inventory Turnover	2.59

Taxes

Income Tax	-187.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +95.35% in the last 52 weeks. The beta is 0.85, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.85
52-Week Price Change	+95.35%
50-Day Moving Average	33.83
200-Day Moving Average	29.11
Relative Strength Index (RSI)	47.93
Average Volume (20 Days)	6,603,591

Short Selling Information

The latest short interest is 33.35 million, so 2.88% of the outstanding shares have been sold short.

Short Interest	33.35M
Short Previous Month	26.65M
Short % of Shares Out	2.88%
Short % of Float	n/a
Short Ratio (days to cover)	5.60

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $17.35 billion and earned $1.57 billion in profits. Earnings per share was $1.34.

Revenue	17.35B
Gross Profit	9.03B
Operating Income	4.01B
Pretax Income	1.38B
Net Income	1.57B
EBITDA	5.00B
EBIT	4.01B
Earnings Per Share (EPS)	$1.34

Full Income Statement

Balance Sheet

The company has $3.74 billion in cash and $16.93 billion in debt, giving a net cash position of -$13.18 billion or -$11.32 per share.

Cash & Cash Equivalents	3.74B
Total Debt	16.93B
Net Cash	-13.18B
Net Cash Per Share	-$11.32
Equity (Book Value)	8.23B
Book Value Per Share	7.07
Working Capital	178.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.71 billion and capital expenditures -$542.00 million, giving a free cash flow of $1.17 billion.

Operating Cash Flow	1.71B
Capital Expenditures	-542.00M
Depreciation & Amortization	997.00M
Net Borrowing	-469.00M
Free Cash Flow	1.17B
FCF Per Share	$1.01

Full Cash Flow Statement

Margins

Gross margin is 52.06%, with operating and profit margins of 23.09% and 9.02%.

Gross Margin	52.06%
Operating Margin	23.09%
Pretax Margin	7.95%
Profit Margin	9.02%
EBITDA Margin	28.84%
EBIT Margin	23.09%
FCF Margin	6.76%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.93%
Shareholder Yield	n/a
Earnings Yield	4.05%
FCF Yield	3.03%

Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $40.90, which is 23.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$40.90
Price Target Difference	23.16%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (3Y)	1.38%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date	Jul 1, 2004
Split Type	Forward
Split Ratio	2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.79 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.79
Piotroski F-Score	7